Gralise is a neuropathic pain relief drug owned by Almatica. It contains gabapentin as the active ingredient and was first authorized for market use on 28 January, 2011.

When will Gralise generic be available?

The generics of Gralise could be available after 26 February, 2024. This is due to the expiry of the last patent titled 'Methods of treatment using a gastric retained gabapentin dosage' (US7438927).

Gralise uses

Gralise uses gabapentin to provide relief from neuropathic pain, especially when associated with postherpetic neuralgia. It is available in the form of oral tablets.

Gralise patent expiration

Gralise holds a total of 5 patents, with 4 already expired. The last remaining patent (US7438927) is expected to expire on 26 February, 2024, possibly paving the way for Gralise generics. Below are the details of the patent:

EPO Oppostions filed on Gralise

Gralise dosage

Want to ask something?